Vyvanse · DIN 02347172 · 60 mg · capsule
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Vyvanse (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Vyvanse · DIN 02347172
Manufacturer: Takeda Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2021-06-24 · brand VYVANSE · ATC N06BA12 LISDEXAMFETAMINE · form Capsule · route Oral · ingredients LISDEXAMFETAMINE DIMESYLATE 60 MG · company Takeda canada inc · schedule Controlled drugs (cdsa i)
Ministry pays: $1.2634 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02347172)
Source record
DIN 02347172: Vyvanse
Raw flags: sec3=Y
Item: 282000063; group id 515; item number 1369; lccId None; manufacturer id TAK
Source form: Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $5.3502; ministry $1.2634
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347172
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83256
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Apo-Lisdexamfetamine Capsules · DIN 02546701 · $1.2634
Jamp Lisdexamfetamine · DIN 02535173 · $1.2634
Sandoz Lisdexamfetamine Capsules · DIN 02546299 · $1.2634
Taro-Lisdexamfetamine · DIN 02558769 · $1.2634
Teva-Lisdexamfetamine · DIN 02545934 · $1.2634
Shortage status: resolved shortage (ended December 11, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02347172
Shortage record checked October 6, 2026